Skip to main content
ABION Inc. logo

ABION Inc. — Investor Relations & Filings

Ticker · 203400 ISIN · KR7203400007 KO Professional, scientific and technical activities
Open in API
Filings indexed 408 across all filing types
Latest filing 2025-09-25 Share Issue/Capital Cha…
Country KR South Korea
Listing KO 203400

About ABION Inc.

https://abionbio.com/en/

ABION Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative medicines, focusing on first-in-class and best-in-class therapeutics for oncology and viral diseases. The company's lead oncology asset is ABN401, a selective c-Met tyrosine kinase inhibitor (TKI) designed to treat non-small cell lung cancer (NSCLC) with MET mutations, which has shown a favorable safety profile. Another key pipeline candidate is ABN501, a novel monoclonal antibody targeting Claudin-3 for various cancers. Beyond oncology, ABION is developing ABN101, a second-generation Interferon-β formulated as a broad-spectrum anti-viral inhaler for respiratory infections. The company aims to commercialize its assets in global markets through internationally recognized clinical processes.

Recent filings

Filing Released Lang Actions
[기재정정]증권신고서(지분증권)
Share Issue/Capital Change Classification · 90% confidence The document is a corrected securities registration statement (“증권신고서(지분증권) 정정신고”) relating to a paid‐in capital increase (유상증자) for issuing new shares, detailing terms of the share issuance, use of proceeds, ratio, discount, and history of the filing. This is a substantive share‐issue disclosure—not merely an announcement or a regulatory certification—so it falls under the Share Issue/Capital Change category (SHA).
2025-09-25 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' which translates to 'Report on Ownership Status of Certain Securities by Executives and Major Shareholders.' It includes detailed information about the ownership of securities by an executive named 김종란, including dates, types of securities, quantities, and changes in holdings. The document is addressed to regulatory bodies such as the Securities and Futures Commission and the Korea Exchange. This type of filing corresponds to insider or director share transactions reporting. Given the content and purpose, this matches the definition of 'Director's Dealing' filings, which report personal share transactions by company directors and executives. The document length is 2483 characters, which is consistent with a detailed insider transaction report rather than a full financial report or announcement. Therefore, the correct classification is DIRS (Director's Dealing).
2025-09-24 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act (Article 147). It details the shareholding status, changes in ownership, and contractual relationships (such as collateral agreements) of major shareholders and their special related parties. This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema.
2025-09-18 Korean
[기재정정]타법인주식및출자증권처분결정
Capital/Financing Update Classification · 95% confidence The document is a regulatory filing from a Korean company (Abion) regarding the 'Decision to Dispose of Shares and Equity Securities of Other Corporations'. It details a correction (amendment) to a previously filed disclosure concerning the disposal amount of shares in another company (Vivozon). This type of disclosure regarding corporate asset disposal or investment changes falls under general regulatory filings as it does not fit into specific categories like M&A (which usually implies control changes or mergers) or share buybacks (which would be POS). Given the nature of the disclosure as a regulatory update, RNS is the most appropriate classification.
2025-09-16 Korean
전환사채(해외전환사채포함)발행후만기전사채취득
Capital/Financing Update Classification · 100% confidence The document is a regulatory filing from a Korean company (Abion) regarding the 'Acquisition of Convertible Bonds before Maturity'. This type of filing details changes to the company's capital structure and debt obligations. Since it specifically relates to the company's financing activities and capital structure changes, it falls under the 'Capital/Financing Update' category.
2025-09-12 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details the share ownership, changes in holdings, and contractual relationships (such as collateral agreements) of major shareholders and their special related parties. This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema.
2025-09-12 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.